<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: EC approves Immuno-Oncology Combination, Bristol-Myers Squibbs Opdivo (nivolumab) + Yervoy  (ipilimumab) Regimen, for Treatment of Advanced Melanoma	</title>
	<atom:link href="https://www.worldpharmatoday.com/press-releases/ec-approves-immuno-oncology-combination-bristol-myers-squibbs-opdivo-nivolumab-yervoy-ipilimumab-regimen-for-treatment-of-advanced-melanoma/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com/press-releases/ec-approves-immuno-oncology-combination-bristol-myers-squibbs-opdivo-nivolumab-yervoy-ipilimumab-regimen-for-treatment-of-advanced-melanoma/</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Tue, 10 May 2016 18:30:00 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>
</channel>
</rss>
